B
TBIO

Bailard’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Bailard’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-13,200
Closed -$167K – 615
2019
Q2 		$167K Hold
13,200
– – 0.01% 509
2019
Q1 		$135K Buy
+13,200
New +$101K 0.01% 520

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bailard's TBIO Position: Q3 2019 in Review

Bailard sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2019, closing a stake of 13,200 shares — an estimated $167K sold.

Bailard first reported a position in TBIO in Q1 2019 and held it in 2 quarters. The position peaked at $167K in Q2 2019. 67 funds tracked by Wall St. Rank hold TBIO as of Q3 2019.

  • Bailard reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Bailard sold 13,200 Translate Bio, Inc. Common Stock shares in Q3 2019, an estimated $167K.
  • Bailard first reported a position in Translate Bio, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
  • Bailard's Translate Bio, Inc. Common Stock position peaked at $167K in Q2 2019.
  • 67 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2019.

Based on Bailard's 13F filing for Q3 2019, filed 18 Oct 2019.